Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth

Group 1 - Ascendis Pharma reported a nearly doubled total revenue of €720 million for 2025, driven by the global adoption of its endocrinology products [1][7] - The company achieved an operating profit of €10 million in Q4 and generated €73 million in operating cash flow, primarily from YORVIPATH and SKYTROFA [1][2] - Ascendis Pharma holds a 45% market share in the US long-acting growth hormone market for SKYTROFA, with plans for growth through the anticipated FDA approval of TransCon CNP for pediatric achondroplasia [3][4] Group 2 - Despite a full-year net loss of €228 million due to commercial investments, Ascendis Pharma ended the year with a strong cash position of €616 million, bolstered by a $100 million partnership payment from Novo Nordisk [2] - The company's proprietary TransCon technology transforms established drugs into long-acting prodrugs, ensuring predictable and sustained release of medication [2]